Infectious Disease Diagnostics Market Report 2034

Report Description

This report is updated with the latest market data and insights as of June 2026. Base year: 2025  |  Forecast period: 2026-2034

Infectious Disease Diagnostics Market Outlook

According to our latest research, the global infectious disease diagnostics market size in 2025 stands at USD 30.5 billion, with a robust compound annual growth rate (CAGR) of 6.3% expected from 2026 to 2034. This growth trajectory will elevate the market to an estimated USD 53.5 billion by 2034. The expansion of this market is primarily driven by the increasing prevalence of infectious diseases worldwide, coupled with technological advancements in diagnostic methodologies and a rising emphasis on early disease detection and management. The market's momentum is further fueled by the global response to emerging pathogens and the ongoing need for rapid, accurate, and scalable diagnostic solutions across both high-income and resource-constrained healthcare environments.

Get Free Sample Report

Several growth factors are catalyzing the infectious disease diagnostics market in 2025 and beyond. One of the most significant drivers is the persistent and rising burden of infectious diseases such as HIV, hepatitis, tuberculosis, influenza, and continued surveillance for COVID-19 and related respiratory pathogens. The increasing incidence of these diseases, particularly in low- and middle-income countries, has led to heightened demand for reliable diagnostic tools. Furthermore, growing awareness among both healthcare professionals and the general public regarding the importance of timely diagnosis is boosting the adoption of advanced diagnostic technologies. Government initiatives and sustained funding for infectious disease surveillance and control programs are also contributing to the market's expansion by encouraging the implementation of diagnostic solutions in public health settings. The parallel growth of infectious disease therapeutics is reinforcing the need for companion diagnostics that guide appropriate treatment selection and monitoring.

Technological advancements have played a pivotal role in shaping the infectious disease diagnostics landscape heading into 2025. The integration of molecular diagnostics, immunodiagnostics, and next-generation sequencing technologies has enhanced the sensitivity, specificity, and speed of disease detection. Innovations such as point-of-care testing, laboratory automation, and digital health solutions are making diagnostics more accessible and efficient, especially in resource-limited settings. The increasing adoption of multiplex assays, which allow simultaneous detection of multiple pathogens, is streamlining diagnostic workflows and reducing turnaround times significantly. These advancements are not only improving patient outcomes but are also driving the growth of the infectious disease diagnostics market by meeting the evolving needs of healthcare providers, clinical laboratories, and public health agencies. The rise of NGS-based infectious disease testing is particularly noteworthy, as whole-genome sequencing increasingly supports outbreak surveillance and antimicrobial resistance profiling.

Another crucial growth factor is the rising investment from both public and private sectors in research and development activities aimed at combating infectious diseases. Pharmaceutical and biotechnology companies are collaborating with academic and research institutes to develop novel diagnostic assays and platforms. The COVID-19 pandemic established lasting infrastructure and regulatory frameworks that continue to accelerate innovation in this space. Regulatory agencies globally have refined expedited pathways for novel diagnostics, further propelling market growth. The increasing focus on personalized medicine and precision diagnostics is expected to create new opportunities for market players, as tailored diagnostic solutions become integral to effective disease management and antimicrobial stewardship programs.

From a regional perspective, North America currently dominates the infectious disease diagnostics market, accounting for the largest share in 2025, followed by Europe and Asia Pacific. The United States, in particular, has a well-established healthcare infrastructure, high healthcare expenditure, and a proactive approach toward disease surveillance, which collectively drive market growth in the region. Europe is also witnessing steady growth due to the presence of leading diagnostic companies, robust research activities, and supportive government policies. Meanwhile, the Asia Pacific region is poised for the fastest growth during the forecast period, fueled by increasing healthcare investments, rising disease burden, and improving diagnostic capabilities in countries such as China, India, and Japan. The Middle East and Africa and Latin America are gradually catching up, supported by international collaborations and public health initiatives targeting infectious disease control.

Product Type Analysis

The infectious disease diagnostics market is segmented by product type into instruments, reagents and kits, and software and services. Among these, reagents and kits represent the largest segment in 2025, owing to their recurrent use in diagnostic procedures across hospitals, laboratories, and research settings. The consistent demand for reagents and consumables, driven by routine screening and outbreak management, ensures a steady revenue stream for manufacturers. Technological advancements have led to the development of highly sensitive and specific reagents, further boosting their adoption in both traditional and advanced diagnostic platforms. The growing trend of multiplexing, which involves the use of kits capable of detecting multiple pathogens simultaneously, is also contributing to the dominance of this segment. The broader in-vitro diagnostics ecosystem continues to drive reagent innovation as manufacturers race to deliver faster, more sensitive, and cost-effective consumable solutions.

Get Free Sample Report

Instruments, including analyzers, PCR machines, and automated platforms, form the backbone of advanced infectious disease diagnostics. The increasing adoption of automated and high-throughput instruments in clinical laboratories is driven by the need for rapid and accurate results, especially during seasonal outbreaks, pandemics, and large-scale screening programs. The integration of artificial intelligence and machine learning into diagnostic instruments is enhancing analytical capabilities, reducing human error, and improving workflow efficiency. Manufacturers are focusing on developing compact and user-friendly instruments suitable for both centralized and decentralized testing environments, catering to the diverse needs of healthcare providers across all regions.

The software and services segment is gaining traction as digital health solutions become integral to modern diagnostics. Laboratory information management systems (LIMS), data analytics tools, and telemedicine platforms are streamlining diagnostic workflows, enabling remote patient monitoring, and facilitating data-driven decision-making. The increasing adoption of cloud-based solutions and interoperability standards is enhancing collaboration among healthcare providers, laboratories, and public health authorities. Service providers are offering comprehensive solutions, including test interpretation, quality control, and regulatory compliance support, to help laboratories meet stringent accreditation requirements and deliver reliable results consistently.

The role of point-of-care infectious disease testing is gaining increasing prominence as healthcare systems worldwide strive for rapid and decentralized diagnostic solutions. POCT allows for immediate testing and result delivery, which is crucial in managing infectious diseases where timely intervention can significantly alter disease progression and limit transmission. The convenience and speed of POCT are particularly beneficial in remote and resource-limited settings, where access to centralized laboratory facilities may be constrained. This approach not only enhances patient care by enabling prompt treatment decisions but also supports public health efforts in controlling outbreaks by facilitating widespread and efficient testing across community settings.

Overall, the product type segmentation reflects the evolving landscape of infectious disease diagnostics, where the synergy between reagents, instruments, and digital solutions is driving market growth. Companies are increasingly offering integrated product portfolios that combine high-performance instruments with proprietary reagents and advanced software, providing end-to-end solutions for disease detection and management. This holistic approach is expected to further accelerate the adoption of infectious disease diagnostics across various healthcare settings, ensuring timely and accurate diagnosis for improved patient outcomes through 2034.

Report Scope

Technology Analysis

The infectious disease diagnostics market is categorized by technology into immunodiagnostics, molecular diagnostics, microbiology, and others. Immunodiagnostics remains a cornerstone technology in 2025, widely used for its ability to detect antigens or antibodies associated with infectious agents. The popularity of immunodiagnostic tests such as ELISA, rapid diagnostic tests (RDTs), and chemiluminescence assays stems from their reliability, ease of use, and cost-effectiveness. These tests are particularly valuable in resource-limited settings, where quick and affordable diagnostics are essential for disease control. The ongoing development of highly sensitive immunoassays and lateral flow devices is expanding the application scope of immunodiagnostics, making them indispensable in both clinical and field settings globally.

Molecular diagnostics represents the fastest-growing technology segment, driven by its unparalleled sensitivity and specificity in detecting pathogenic DNA or RNA. Techniques such as polymerase chain reaction (PCR), real-time PCR, and next-generation sequencing (NGS) have revolutionized infectious disease diagnostics by enabling early and accurate detection of a wide range of pathogens, including emerging and re-emerging viruses. The COVID-19 pandemic highlighted the critical role of molecular diagnostics in large-scale testing and surveillance, prompting significant and sustained investments in this technology through 2025. The development of multiplex PCR assays and portable molecular platforms is further expanding the reach of molecular diagnostics, making them accessible to decentralized and point-of-care settings across all income levels.

Microbiology-based diagnostics, including culture methods, microscopy, and biochemical tests, continue to play a vital role in the identification and characterization of infectious agents, particularly bacteria and fungi. While these methods are time-tested and provide valuable information on pathogen susceptibility and resistance, their longer turnaround times and labor-intensive nature have led to a gradual shift toward automated and rapid diagnostic technologies. Nonetheless, microbiology remains essential for comprehensive infectious disease management, especially in cases of antimicrobial resistance and complex infections where detailed pathogen profiling is required by clinicians and infection control specialists.

Other emerging technologies, such as biosensors, nanotechnology-based assays, and digital PCR, are beginning to make meaningful inroads into the infectious disease diagnostics market in 2025. These innovations offer the potential for ultra-sensitive, rapid, and multiplexed detection of pathogens, addressing the limitations of traditional diagnostic methods. The integration of artificial intelligence and machine learning algorithms with diagnostic platforms is also enhancing data analysis, interpretation, and clinical decision support capabilities. The growing interest in advanced molecular diagnostic platforms reflects a broader shift toward precision medicine, where comprehensive pathogen profiling informs tailored treatment regimens and infection control strategies.

Application Analysis

The application landscape of the infectious disease diagnostics market is broad in 2025, encompassing hepatitis, HIV, influenza, tuberculosis, COVID-19, and other infections. Hepatitis diagnostics remain a significant segment, driven by the global burden of hepatitis B and C infections, which affect hundreds of millions of individuals worldwide. Early and accurate diagnosis is critical for effective disease management, prevention of transmission, and initiation of antiviral therapy. The availability of advanced serological and molecular assays has improved the detection of hepatitis viruses, supporting public health efforts to eliminate viral hepatitis as a major health threat by 2030 as targeted by the World Health Organization.

HIV diagnostics continue to be a major focus area in 2025, particularly in regions with high prevalence rates such as sub-Saharan Africa and parts of Asia. Routine screening, early diagnosis, and monitoring of HIV infection are essential components of global HIV/AIDS control programs. The development of rapid, point-of-care HIV tests has significantly increased access to diagnostics, especially in remote and underserved areas. Continuous innovation in molecular and immunoassay technologies is enhancing the accuracy and reliability of HIV diagnostics, supporting global efforts to achieve the UNAIDS 95-95-95 targets. The diagnostics segment also benefits from growing interest in sexually transmitted infection testing more broadly, as integrated STI screening programs combine HIV with syphilis, gonorrhea, and chlamydia detection.

The influenza diagnostics segment is characterized by seasonal demand fluctuations, driven by annual outbreaks and ongoing pandemic preparedness concerns. Rapid influenza diagnostic tests (RIDTs), molecular assays, and multiplex panels are widely used for the detection and differentiation of influenza virus strains. The ongoing development of universal influenza vaccines and antiviral therapies underscores the importance of timely and accurate diagnostics in controlling influenza transmission and reducing disease burden. Public health agencies and healthcare providers rely on robust diagnostic infrastructure to monitor influenza activity and respond to emerging strains in real time.

Tuberculosis (TB) diagnostics remain a critical component of infectious disease control in 2025, particularly in high-burden countries across South Asia, Southeast Asia, and sub-Saharan Africa. The widespread adoption of molecular tests such as GeneXpert MTB/RIF and next-generation cartridges has revolutionized TB diagnosis by enabling rapid detection of Mycobacterium tuberculosis and drug resistance markers simultaneously. Despite these advances, challenges persist in ensuring widespread access to TB diagnostics in the most resource-limited settings. Ongoing research and development efforts are focused on improving the sensitivity, affordability, and scalability of TB diagnostic tools to support global TB elimination goals set for 2035.

The COVID-19 application segment has transitioned from emergency-phase testing to an endemic surveillance model by 2025. While testing volumes have normalized compared to pandemic peaks, COVID-19 diagnostics remain an important component of respiratory disease panels and hospital admission workflows. The infrastructure, regulatory frameworks, and manufacturing capabilities established during the pandemic continue to benefit the broader infectious disease diagnostics market, enabling faster responses to future outbreaks and facilitating the rapid development of diagnostics for novel emerging pathogens.

End User Analysis

The infectious disease diagnostics market is segmented by end user into hospitals, diagnostic laboratories, academic and research institutes, and others. Hospitals represent the largest end-user segment in 2025, driven by the high volume of diagnostic tests performed in inpatient and outpatient settings. Hospitals rely on a wide array of diagnostic tools to manage infectious disease outbreaks, monitor patient progress, and guide treatment decisions. The integration of advanced diagnostic platforms, automation, and electronic health records is enhancing diagnostic accuracy and operational efficiency in hospital laboratories. The growing emphasis on infection prevention and control is further increasing the adoption of rapid and point-of-care testing solutions in hospital settings globally.

Diagnostic laboratories play a central role in the infectious disease diagnostics ecosystem, providing specialized testing services to hospitals, clinics, and public health agencies. These laboratories are equipped with state-of-the-art instruments and skilled personnel, enabling them to perform complex molecular, serological, and microbiological assays. The trend toward laboratory consolidation and centralization is driving investments in high-throughput automation and digital solutions, enabling labs to handle large test volumes efficiently. Outsourcing of diagnostic services to commercial laboratories is also on the rise, particularly in regions with limited in-house laboratory capacity, fueling growth for independent laboratory networks.

Academic and research institutes contribute significantly to the development and validation of novel diagnostic technologies. These institutions conduct basic and translational research aimed at understanding pathogen biology, disease mechanisms, and host-pathogen interactions. Collaborative efforts between academia, industry, and government agencies are accelerating the translation of research findings into commercially viable diagnostic products. Academic institutes also play a crucial role in training the next generation of scientists and clinicians, ensuring a skilled workforce that sustains innovation across the diagnostics industry.

The others category includes clinics, ambulatory care centers, and public health laboratories, each playing a unique role in the infectious disease diagnostics landscape. Public health laboratories are at the forefront of disease surveillance, outbreak investigation, and response activities, often working in close collaboration with international organizations such as the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC). The increasing focus on decentralized testing and community-based healthcare is expanding the role of non-traditional end users in infectious disease diagnostics, ensuring broader access to timely and accurate testing services at the population level.

Opportunities & Threats

The infectious disease diagnostics market presents significant opportunities for growth and innovation heading through 2034. One of the most promising opportunities lies in the continued expansion of point-of-care testing solutions, which are transforming the diagnostic landscape by enabling rapid, on-site detection of infectious agents. The development of portable, user-friendly devices capable of delivering accurate results within minutes is particularly beneficial in remote, resource-limited, and emergency settings. Companies investing in POCT technologies are well-positioned to capture substantial market share, especially as healthcare systems prioritize decentralized testing and early disease detection. Additionally, the integration of digital health solutions, such as telemedicine and mobile health applications, is creating new avenues for remote diagnosis, patient monitoring, and data-driven disease management.

Another major opportunity is the growing emphasis on personalized and precision medicine, which is driving demand for advanced molecular diagnostics and biomarker-based assays. The ability to identify specific pathogens, resistance genes, and patient risk profiles is enabling tailored treatment strategies and improving clinical outcomes. The increasing adoption of next-generation sequencing and multiplex assays is expanding the scope of infectious disease diagnostics, allowing simultaneous detection of multiple pathogens and comprehensive characterization of disease etiology. Strategic collaborations between diagnostic companies, pharmaceutical firms, and research institutions are fostering innovation and accelerating the development of novel diagnostic platforms. The rising prevalence of antimicrobial resistance is also creating substantial opportunities for diagnostics that support antibiotic stewardship and guide targeted therapy decisions.

Despite these opportunities, the infectious disease diagnostics market faces several restraining factors. One of the primary challenges is the high cost associated with advanced diagnostic technologies, which can limit their adoption, particularly in low- and middle-income countries. The need for specialized equipment, skilled personnel, and robust infrastructure can pose significant barriers to market entry and expansion in emerging regions. Regulatory complexities and lengthy approval processes can also delay the commercialization of novel diagnostic products, particularly for multiplex and NGS-based platforms. Additionally, issues related to test accuracy, sensitivity, and specificity can impact clinical decision-making and patient outcomes. Addressing these challenges will require concerted efforts from industry stakeholders, policymakers, and healthcare providers to ensure affordable, accessible, and reliable diagnostic solutions for all populations globally.

Regional Outlook

The regional distribution of the infectious disease diagnostics market reveals distinct trends and growth opportunities across different geographies. North America leads the market with an estimated value of USD 11.7 billion in 2025, driven by a well-established healthcare infrastructure, high healthcare spending, and proactive disease surveillance programs. The United States accounts for the majority of the regional market share, supported by the presence of leading diagnostic companies, advanced laboratory networks, and favorable reimbursement policies. Canada also contributes significantly to market growth, with a strong focus on public health initiatives and research collaborations aimed at combating both endemic and emerging infectious diseases.

Get Free Sample Report

Europe holds the second-largest share of the infectious disease diagnostics market, valued at approximately USD 8.4 billion in 2025. The region benefits from robust healthcare systems, extensive research activities, and supportive regulatory frameworks that facilitate the adoption of innovative diagnostic technologies. Countries such as Germany, the United Kingdom, France, and Italy are at the forefront of market growth, driven by increasing investments in healthcare infrastructure, rising disease awareness, and active participation in global health initiatives. The European market is expected to grow at a steady pace, with a projected CAGR of 5.9% during the 2026-2034 forecast period.

The Asia Pacific region is emerging as the fastest-growing market for infectious disease diagnostics, with an estimated value of USD 6.5 billion in 2025. Rapid urbanization, rising healthcare expenditure, and increasing prevalence of infectious diseases are driving demand for advanced diagnostic solutions in countries such as China, India, Japan, and South Korea. Government initiatives aimed at strengthening healthcare infrastructure, expanding access to diagnostics, and promoting disease surveillance are supporting market growth across the region. Asia Pacific is expected to witness a CAGR of 7.8% from 2026 to 2034, outpacing all other regions. The strong pipeline of domestically developed diagnostics and the influence of regional manufacturers is also contributing to competitive dynamics in this market. The growing importance of broader diagnostic innovation across life sciences sectors in Asia Pacific reflects the region's increasing investment in diagnostic research and manufacturing capacity. Latin America and the Middle East and Africa collectively account for the remaining market share, with growing investments in public health and international collaborations aimed at improving disease detection and control across underserved populations.

Competitor Outlook

The competitive landscape of the infectious disease diagnostics market in 2025 is characterized by intense rivalry among established global players, emerging startups, and regional companies. Market leaders are focusing on expanding their product portfolios, enhancing technological capabilities, and strengthening distribution networks to maintain their competitive edge. Strategic collaborations, mergers and acquisitions, and partnerships with research institutions are common strategies employed to accelerate innovation and market penetration. The influx of new entrants, particularly in the point-of-care and molecular diagnostics segments, is intensifying competition and driving greater price competitiveness, making advanced diagnostics more accessible to a broader customer base globally.

Innovation remains a key differentiator in the infectious disease diagnostics market, with companies investing heavily in research and development to introduce novel assays, platforms, and digital solutions. The rapid evolution of molecular diagnostics, immunoassays, and next-generation sequencing technologies is enabling market players to address unmet clinical needs and respond swiftly to emerging infectious threats. Regulatory compliance, quality assurance, and customer support are critical factors influencing purchasing decisions, prompting companies to invest in robust quality management systems and comprehensive service offerings. The ability to provide integrated, end-to-end diagnostic solutions is increasingly valued by healthcare providers seeking streamlined workflows and improved patient outcomes.

The COVID-19 pandemic permanently reshaped the competitive dynamics of the market, and the capabilities built during that period continue to benefit leading players in 2025. Several companies achieved rapid growth through the development and commercialization of SARS-CoV-2 diagnostic tests, and they have since leveraged their expanded manufacturing and distribution capabilities to compete across other disease areas. Companies are also actively exploring opportunities in emerging markets, where rising disease burden and improving healthcare infrastructure present significant growth potential for both established multinationals and agile regional players.

Major companies operating in the infectious disease diagnostics market include Abbott Laboratories, F. Hoffmann-La Roche Ltd., bioMérieux SA, Becton, Dickinson and Company (BD), Danaher Corporation (Cepheid), Thermo Fisher Scientific Inc., Siemens Healthineers AG, QIAGEN N.V., Hologic, Inc., and Bio-Rad Laboratories, Inc. Abbott Laboratories is renowned for its broad portfolio of immunoassays and molecular diagnostics, with a strong focus on point-of-care solutions such as the ID NOW platform. Roche is a leader in molecular diagnostics, offering a comprehensive range of PCR and next-generation sequencing platforms serving clinical and public health laboratories. bioMérieux specializes in microbiology and immunoassays, with a global presence and extensive research collaborations supporting rapid diagnostic innovation. BD is a major player in microbiology and molecular diagnostics, known for its automated platforms and innovative solutions for infectious disease detection and antimicrobial resistance monitoring.

Danaher Corporation, through its subsidiary Cepheid, has established a strong foothold in molecular diagnostics with its GeneXpert platform, which is widely deployed for tuberculosis, COVID-19, HIV, and other infectious diseases in both high-income and resource-limited settings. Thermo Fisher Scientific offers a diverse portfolio of diagnostic reagents, instruments, and services, catering to both clinical and research applications globally. Siemens Healthineers is recognized for its advanced laboratory automation and immunoassay systems, while QIAGEN is a leader in sample preparation and molecular diagnostics. Hologic focuses on women's health and infectious disease diagnostics, with a strong presence in molecular testing for sexually transmitted infections and respiratory pathogens. Bio-Rad Laboratories is known for its innovative PCR and immunoassay technologies, serving both clinical and research markets with quality-driven solutions.

Additional notable competitors include QuidelOrtho Corporation, formed through the merger of Quidel and Ortho Clinical Diagnostics, which has a strong position in immunoassay and rapid diagnostic testing. Meridian Bioscience offers a broad range of reagents and kits for gastrointestinal and respiratory pathogen detection. Sysmex Corporation and Seegene Inc. are prominent in automation and multiplex molecular diagnostics respectively, while Grifols S.A. and Revvity Inc. round out the competitive field with specialized offerings in blood screening and life sciences tools. These companies are continuously investing in research and development, strategic acquisitions, and global expansion to strengthen their market positions. The competitive landscape is expected to remain highly dynamic through 2034, with ongoing innovation, regulatory advancements, and evolving customer needs shaping the future of the infectious disease diagnostics market.

Key Players

• Abbott Laboratories
• F. Hoffmann-La Roche Ltd
• bioMérieux SA
• Becton, Dickinson and Company (BD)
• Thermo Fisher Scientific Inc.
• Siemens Healthineers AG
• Danaher Corporation
• QIAGEN N.V.
• Hologic, Inc.
• Bio-Rad Laboratories, Inc.
• Cepheid (a Danaher company)
• QuidelOrtho Corporation
• Meridian Bioscience, Inc.
• Sysmex Corporation
• OraSure Technologies, Inc.
• Seegene Inc.
• Grifols S.A.
• Revvity Inc.